FROM DATA TO DISCOVERY: THE ART OF DXA ANALYSIS IN RESEARCH
If you’re planning a clinical study or developing a new treatment focusing on bone health, osteoporosis, obesity, and related conditions, perhaps you should consider incorporating DXA!
DXA – Dual-Energy X-ray Absorptiometry or DEXA – is a valuable tool in clinical trials. Its importance lies in its ability to accurately measure bone mineral density and body composition, providing quantitative data that can be crucial for assessing the efficacy of interventions and treatments.
Join our panel of experts to discuss the significance of DXA, exploring practical use cases and uncover how IAG excels in effectively managing its clinical trials.
Presenter: Michael Clark
A Senior Clinical Director with extensive experience in undertaking strategic planning, oversight and execution of clinical programs and leading staff across multiple project areas globally. Skilled in needs assessment, quality assurance, managing programmes, communicating deadlines and completing projects within budget and on-time. Committed to achieving and exceeding targets in a drive to meet business objectives with strong clinical expertise and stakeholder management abilities.
Presenter: Prof. Mikael Boesen
Prof. Boesen, IAG’s Therapeutic Area Lead for Rheumatic Diseases and Auto-Immunity, is a professor of radiology with focus on musculoskeletal imaging and development of novel therapeutics for rheumatic and autoimmune conditions. He heads musculoskeletal imaging and research groups at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and expert reader on trials. He is an author of 200+ articles, chapters and abstracts and he has served as supervisor of more than 30 PhD students and postdocs. He brings together cross-therapeutic area expertise into musculoskeletal imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in EU and the USA, all of which he uses to help drug development companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy.
Presenter: Cristiano Costa
With over a decade of experience in cross-sectional diagnostic imaging and a background in healthcare management Cristiano brings a blend of clinical expertise and administrative skills to the healthcare industry. This multifaceted experience contributes to the enhancement of healthcare delivery and the optimization of clinical workflows, enabling streamlined and efficient processes.
Moderator: Julia O’Lynn
With 20+ years of expertise in targeted drug development and advanced radiologic imaging, Julia advises life science companies on how to accelerate drug development and commercialization.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: ia-grp.com
Reach out: contact@ia-grp.com
Follow the Company: Linkedin